COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success

Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial

Fast Skeletal Muscle Troponin Activator CK-4015089 Improves Muscle Function in a FSHD Mouse Model with Muscle Weakness

Feasibility Assessment of Using the MiToS Staging System for Conducting Economic Evaluation in Amyotrophic Lateral Sclerosis

Time From Amyotrophic Lateral Sclerosis Symptom Onset to Key Disease Milestones: Analysis of Data From a Multinational Cross-Sectional Survey

Site and Participant Perspectives on Participating in an ALS Trial Designed to Reduce Burden: COURAGE-ALS

COURAGE-ALS: Results of the Phase 3 Clinical Trial of Reldesemtiv in ALS

Investigating Geographical Differences in Time from ALS Symptom Onset to Key Disease Milestones: Data from a Real-World Survey

Plasma Neurofilament Analysis in VITALITY-ALS: Analysis at Baseline, Longitudinal, and by Rate of Disease Progression

Hospitalizations in COURAGE-ALS and their Relationship to ALS